Investigational drug · Phase 2
ACDN-01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ACDN-01"
First trial start
2024
Jun 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ACDN-01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Stargardt Disease
- Cone Rod Dystrophy
- Juvenile Macular Degeneration
- Stargardt Disease 1
Approved drugs for the same conditions: Wet macular degeneration · Rare and genetic disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "ACDN-01" as an intervention, largest first.
- Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)Active, not recruiting
Ascidian Therapeutics, IncIndustry
NCT06467344 · 15 participants (planned) · Start Jun 11, 2024 · Primary completion Aug 1, 2030
Drug: ACDN-01 · For: Stargardt Disease; Cone Rod Dystrophy; Juvenile Macular Degeneration and 1 more
Sites: San Francisco, California; Gainesville, Florida; Miami, Florida · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Stargardt's Disease: Molecular Pathogenesis and Current Therapeutic Landscape.
Dayma K, Rajanala K, Upadhyay A · Int J Mol Sci 2025
Also in development for Stargardt Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.